carmustine has been researched along with tyrosine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dröge, W; El Benna, J; Galter, D; Klein, G; Schmid, E | 1 |
Huynh, H; Leong, CT; Nguyen, TH; Ong, CK; Panasci, L; Wong, E | 1 |
2 other study(ies) available for carmustine and tyrosine
Article | Year |
---|---|
Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation.
Topics: Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Antioxidants; Buthionine Sulfoximine; Carmustine; CHO Cells; Cricetinae; Enzyme Induction; Insulin; Oxidation-Reduction; Phosphoric Monoester Hydrolases; Phosphorylation; Protein-Tyrosine Kinases; Receptor, Insulin; Transfection; Tyrosine | 1998 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carmustine; Caspase 3; Caspase 7; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Proliferation; Cell Survival; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Complementary; Dose-Response Relationship, Drug; G2 Phase; Genes, p53; Genetic Therapy; Humans; Immunoprecipitation; In Vitro Techniques; Male; Mice; Mice, SCID; Mitosis; Mutation; Nasopharyngeal Neoplasms; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Time Factors; Transfection; Tumor Suppressor Protein p53; Tyrosine; Up-Regulation | 2005 |